Morgan Stanley initiated coverage on BioAge Labs with a new price target
$BIOA
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley initiated coverage of BioAge Labs with a rating of Overweight and set a new price target of $40.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2025 | Mkt Perform | William Blair | |
| 12/10/2024 | $40.00 → $5.00 | Overweight → Underweight | Morgan Stanley |
| 12/9/2024 | $42.00 → $7.00 | Buy → Hold | Jefferies |
| 12/9/2024 | $45.00 → $7.00 | Buy → Neutral | Citigroup |
| 10/21/2024 | $45.00 | Buy | Citigroup |
| 10/21/2024 | $42.00 | Buy | Jefferies |
| 10/21/2024 | $40.00 | Overweight | Morgan Stanley |
8-K - BioAge Labs, Inc. (0001709941) (Filer)
10-Q - BioAge Labs, Inc. (0001709941) (Filer)
8-K - BioAge Labs, Inc. (0001709941) (Filer)
4/A - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4/A - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4/A - BioAge Labs, Inc. (0001709941) (Issuer)
William Blair initiated coverage of BioAge Labs with a rating of Mkt Perform
Morgan Stanley downgraded BioAge Labs from Overweight to Underweight and set a new price target of $5.00 from $40.00 previously
Jefferies downgraded BioAge Labs from Buy to Hold and set a new price target of $7.00 from $42.00 previously
SC 13G - BioAge Labs, Inc. (0001709941) (Subject)
SC 13G - BioAge Labs, Inc. (0001709941) (Subject)
SC 13D - BioAge Labs, Inc. (0001709941) (Subject)
Company enters option agreement with JiKang Therapeutics to in-license novel APJ agonist antibody New composition of matter IP filed for chemically distinct, orally active, and highly potent small molecule APJ agonists EMERYVILLE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced advances in its apelin receptor (APJ) agonist programs that strengthen the Company's pipeline of approaches for obesity and other indications. BioAge has entered into an option agreement with JiKang Therapeutics ("JiK
IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor agonistsInternally discovered compound has a novel binding site and potential best-in-class profile supporting once daily dosing EMERYVILLE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced completion of IND-enabling studies for BGE-102 and updated clinical development milestones for the compound.
EMERYVILLE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • Jefferies Global Healthcare Conference (New York, June 3–5, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. • Goldman Sachs 46th Annual Global Healthcare Conference (Miami, June 9–11, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are sche